Renal pelvis & ureter cancer

The renal pelvis collects urine within the kidney, and the ureter carries it to the bladder. Cancer of their lining is usually urothelial carcinoma, also called transitional cell carcinoma in older reports. It shares features with bladder cancer but is not a subtype of renal cell carcinoma.

Smoking and exposure to aristolochic acid increase risk. Report any history of bladder cancer and all herbal products used; a product described as natural is not automatically harmless to the urinary tract. Some cases are associated with Lynch syndrome.

Blood in urine is a common presentation. Flank pain may arise when a tumor or clot obstructs drainage. CT urography examines the collecting system and surrounding structures; MR urography may be used when CT is unsuitable. Cystoscopy checks for a separate bladder tumor.

Ureteroscopy can map the lesion and obtain biopsy or selective urine samples when imaging and cytology do not provide enough information. Small biopsies may underestimate grade or depth, so treatment should not depend on the biopsy wording alone. Ask whether the sample and scan are consistent and whether repeat assessment would change the plan.

Grade is a major clue to biological aggressiveness. High-grade cytology or biopsy, invasive features on imaging and certain histological patterns raise concern. Tumor size, multiple lesions and hydronephrosis add context but should not alone dictate removal of a kidney in an otherwise low-grade case.

For low-risk UTUC, kidney-sparing treatment is generally preferred when complete local control and careful surveillance are feasible. Endoscopic ablation or selected ureteral resection can preserve the kidney. An early second-look ureteroscopy checks for residual tumor; further procedures may be needed.

In the United States, mitomycin gel (Jelmyto) is approved for adults with low-grade UTUC and is delivered to the renal collecting system. It is not an intravenous treatment or an established substitute for surgery in invasive high-grade disease. Ureteral obstruction, kidney injury and infection are important risks; treatment requires a team able to monitor drainage and kidney function.

Radical nephroureterectomy removes the affected kidney, ureter and a cuff of bladder around the ureteral opening. It is a standard approach for high-risk nonmetastatic disease; lymph-node management depends on risk and tumor location. Removing only the kidney leaves a different oncological problem from a complete nephroureterectomy.

Selected distal ureter tumors may allow ureteral resection and reconstruction. A solitary kidney, bilateral tumors or severe chronic kidney disease can make kidney preservation particularly important, even when cancer risk is higher. This requires an explicit discussion of recurrence, progression and possible later radical surgery.

Kidney function may fall after surgery, changing cisplatin eligibility. In suitable high-risk cases, discussing chemotherapy before surgery can therefore be important. After surgery, the POUT randomized trial supports adjuvant gemcitabine–platinum chemotherapy for eligible patients with muscle-invasive or node-positive, nonmetastatic UTUC. Its cisplatin or carboplatin selection reflected renal function; this does not prove that the two are interchangeable in every setting.

Adjuvant immunotherapy may be discussed for selected high-risk patients, but upper-tract subgroups in major urothelial trials are smaller and their benefit is less certain than the overall trial result. Also, a drug approved around cystectomy for muscle-invasive bladder cancer is not automatically approved around nephroureterectomy for UTUC. Confirm the disease site, evidence and local label.

Advanced UTUC is treated as urothelial cancer. In the United States, enfortumab vedotin plus pembrolizumab is approved for adults with locally advanced or metastatic urothelial cancer. Another pathway uses platinum chemotherapy, with avelumab maintenance if disease does not progress. Prior treatment, organ function and adverse-effect risks shape the choice.

Molecular testing can identify susceptible FGFR3 alterations. The US erdafitinib indication requires prior systemic treatment; its label does not recommend use before PD-1/PD-L1 treatment in eligible patients who have not received it. A report showing an FGFR alteration must specify the gene and variant. Trial options should be matched to the upper-tract origin and the treatments already received.

Personal or family histories of colorectal, endometrial and other Lynch-associated cancers can prompt hereditary assessment. Tumor MMR/MSI testing may help identify patients needing germline testing; a tumor result alone does not prove inherited Lynch syndrome. A confirmed inherited finding can affect relatives and screening for other cancers.

Follow-up looks for upper-tract recurrence, a new bladder tumor and spread elsewhere, while monitoring kidney function. A later bladder tumor is not automatically distant metastatic disease. Kidney-sparing treatment needs particularly close upper-tract surveillance; the schedule differs from follow-up after complete nephroureterectomy.

Seek urgent assessment for fever with flank pain, reduced urine output or a blocked nephrostomy. Bring both kidneys’ function tests, CT/MR urography, cytology, ureteroscopy images, pathology and treatment records. Before travel, agree who will manage stents, drainage tubes and repeat scopes.